- Email: [email protected]
Thymic hormones and lymphokines `83, May 31–June 3, 1983, Washington, D.C.
5. G.oldstein, A. L. et al. (I983). Thymosins, pp. 119-132. ht J. F. Bach (ed.), Clinics in immunology and allergy, Vol. 3. W. B. Sanders Co., London. 6. Hersh, E. M. et al. (1983). Elevated serum thymosin eq levels associated with evidence of immune dysregulation
in male homosexuals with a history of infections diseases or Kaposi sarcoma. N. Engl. J. Med. 308:45-56. 7. McClure, J. E. et al. (1982). Immunochemical studies on thymosin: Radioimmunoassay of thymosin txI. J. Immunol. 128:368-375. 8. Naylor, P. H. and Goldstein, A. L.
(in press). Elevated serum thymosin eq as an early marker for acquired immunodeficiency syndrome (AIDS). A. Friedman-Kein (ed) Proceedings of the Conference on Kaposi's Sarcoma. 9. Reuben, J. M. et al. (1983). Immunological characterization of homosexual men. Cancer Res. 43:897-904.
mulatory activity of the partially purified thymus extracts. Certain other thymic factors have also been analyzed. Thymosin [34, including distribution and biosynthesis in many different vertebrate cells and tissues, was presented by Dr. B. L. Horecker (New Jersey). The significance of spermidine and spermine as regulators of thymus extract function was discussed by Dr. K. Folkers (Texas). The concept of small thymic peptides as immunoregulatory agents was reviewed by Dr. C. Birr (West Germany). Several short papers were included on the possible role of the thymus in AIDS. The second session, co-chaired by Drs. R. Gallo and M. Chirigos (Maryland), focused on the chemistry and biology of lymphokines. Dr. S. Mizel (Pennsylvania) described the preparation of antibodies against interleukin 1. Dr. T. D. Copeland (Maryland) characterized thymus cell growth factor obtained from continuous cell cultures of thymus cells in vitro using immunoaffinity methods. Dr. S. Rosenberg (Maryland) reviewed the role of lymphokines and adoptive immunotherapy concerning both experimental animals and man. The biological properties of interleukin 3, a soluble factor from T cells that activates other T cells, was illustrated by Dr. J. Ihle (Maryland). Colony stimulating factor, which activates mononuclear phagocytes, was described by Dr. E. R. Stanley (New York). Lymphotoxins, their nature, and their role in immunity was presented by Dr. G. Granger (California). Purification of human lymphotoxins from a tumor cell line was discussed by Dr. B. Aggarwal (California). The third session, co-chaired by
Drs. J. Oppenheim (Maryland) and A. deWeck (Switzerland), highlighted the immunoregulation and the role of various factors, such as thymosin extracts and lymphokines. Dr. deWeck discussed aging as related to lymphocyte receptors, lymphokines, and lymphocytes. Dr. W. Ershler (Vermont) reviewed the role of thymosin in augmenting antibody formation by lymphocytes from elderly individuals. Dr. K. A. Smith (New Hampshire) dealt with interleukins as immunoregulatory factors. Drs. N. Hall (Washington, D.C.) and R. Rebar (California) reviewed the interactions between the immune system and the central nervous system through immunomodulatory factors. Dr. E. Pick (Israel) discussed various biochemical activities of lymphokines. Dr. C. Sorg (West Germany) elaborated on macrophage migration inhibitory factor. Dr. J. Vilcek (New York) described human immune interferon internalization and specific cell receptors. The fourth session, co-chaired by Drs. E. Garaci (Italy) and J. Hadden (Florida), concentrated on the pharmacology of various interieukins. Dr. B. W. Papermaster (Missouri) reviewed purification and biological properties of human lymphoblastoid macrophage activating factors, while Dr. G. J. Todaro (Washington) discussed tumor inhibitory factors produced by tumor cells. Dr. Djerassi (Pennsylvania) reviewed the properties of inhibitory factors released by normal cells in culture. The effects of thymosin on cell-mediated immunity, immunoregulatory T cells, and tumor cells were explored by a number of speakers.
MEETING REPORT Thymic Hormones and Lymphokines '83, May 31-June 3, 1983, Washington, D.C. Herman Friedman, Ph.D. Department of Medical Microbiology and Immunology University of South Florida Tampa. Florida
The meeting consisted of five halfday plenary sessions, five poster sessions, and a final panel discussion summarizing the various topics. The first plenary session, co-chaired by Drs. J. F. Bach (France) and H. Friedman (Florida), dealt with the chemistry of thymic hormones. Recent developments in the biochemistry of thymulin, a nonapeptide, initially identified by Bach and his group, was reviewed by M. Dardanne (France). Thymulin, the new term for the biological active serum peptide formally called Factor Thymique Serique, readily binds to the metal zinc. The conjugate of the nonapeptide and zinc accounts for all of the biologic activity of the native peptide. It has been synthesized and shown to activate immature lymphoid cells. The biochemistry and structure of thymosin factors were described by Dr. T. Low (Washington, D.C.). A large family of peptides has now been identified in the original thymosin fraction-5, which has been used both in experimental animal and human studies in terms of modulation of thymus function. Thymosin txI has been sequenced and synthesized and shown to have much of the immunosti-
128
0197-1859/83/S03.00
Clinical ImmunologyNewsletter
The final plenary session, co-chaired by Drs. R. Oldham (Maryland) and P. Chretien (Maryland), dealt with clinical applications of thymosin and interleukins. A large number of studies have now been performed in various medical centers concerning factors such as interferon, interleukins, lym-
Editors: Herman Friedman Mario R. Escobar Noel R. Rose
phokines, and thymus extracts, including thymulin, thymosin fraction-5, and thymosin al- At the present time, there is no general consensus as to whether or not significant augmentation of immune responses occurs with these materials and whether or not there are significant clinical improve-
ments in patients with various diseases, including cancer and immunodeficiencies. It was generally agreed that further studies are warranted to ascertain the usefulness of these factors in clincial situations.
Contributing Editors: John R. Kateley, Jr., Ph.D., Edward W. Sparrow Hospital; Stanley S. Lefkowitz, Ph.D., Texas Tech University; Bruce S. Rabin, M.D., Ph.D., University of Pittsburgh Medical School; Gilberto E. Rodriguez, M.D., Medical College of Virginia; lohn L. Sever, M.D., Ph.D., National Institutes of Health; Steven Specter, Ph.D., University of South Florida College of Medicine; Roy W. Stevens, Ph.D., State of New York Department of Health; Gabriel W. Virella, M.D., Ph.D., Medical University of South Carolina; Kenneth W. Walls, Ph.D., Centers for Disease Control; Theresa L. Whiteside, Ph.D., University of Pittsburgh Medical School. Consulting Editors: Joseph A. Bellanti, M.D., Georgetown University School of Medicine; Rebecca H. Buckley, M.D., Duke University Medical Center; John L. Fahey, M.D., UCLA School of Medicine; H. Hugh Fudenberg, M.D., Medical University of South Carolina; Erwin Neter, M.D., Children's Hospital and SUNY; Gerald M. Penn, M.D., Ph.D., Grant Hospital; Robert F. Ritchie, M.D., Foundation for Blood Research; Andor Szentivanyi, M.D., University of South Florida College of Medicine; Norman Talal, M.D., University of Texas Health Science Center; Eng M. Tan, M.D., Scripps Clinic and Research Foundation; Edmond J. Yunis, M.D., Sidney Farber Cancer Institute. Clinical hnmunology Newsletter is published monthly by Elsevier Science Publishing Co., Inc., 52 Vanderbilt Avenue, New York, NY 10017. Subscription rate is $50.00 for 12 issues including postage and handling in the United States and Canada. Add $14.00 for postage (airmail) in Mexico and Europe and $16.00 for the rest of the world. This newsletter has been registered with the Copyright Clearance Center, Inc. Consent is given for copying articles for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition that the copier pay through the Center the per-page fee stated in the code on each page for copying beyond that permitted by the U.S. Copyright Law. If no code appears on an article, the author has not given broad consent to copy. and permission to copy must be obtained directly from the author. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.
ISSN 0197-1859 CIMNDC 4(9) 113-129, 1983
Address orders, changes of address, and claims for missing issues to Journals Fulfillment Department, Elsevier Science Publishing Co., Inc., 52 Vanderbilt Avenue, New York, NY 10017. Claims for missing issues can be honored only up to three months for domestic addresses and six months for foreign addresses. Duplicate copies will not be sent to replace ones undelivered due to failure to notify Elsevier of change of address.
Elsevier Biomedical
Postmaster: Send address changes to Clhffcal hnmunology Newsletter, Elsevier Science Publishing Co., Inc., 52 Vanderbilt Avenue, New York, NY 10017.
O 1983 Elsevier Science Publishing Co., Inc.
© 1983 by Elsevier Science PublishingCo.. Inc.
0197-]859'83/503.00
129
in male homosexuals with a history of infections diseases or Kaposi sarcoma. N. Engl. J. Med. 308:45-56. 7. McClure, J. E. et al. (1982). Immunochemical studies on thymosin: Radioimmunoassay of thymosin txI. J. Immunol. 128:368-375. 8. Naylor, P. H. and Goldstein, A. L.
(in press). Elevated serum thymosin eq as an early marker for acquired immunodeficiency syndrome (AIDS). A. Friedman-Kein (ed) Proceedings of the Conference on Kaposi's Sarcoma. 9. Reuben, J. M. et al. (1983). Immunological characterization of homosexual men. Cancer Res. 43:897-904.
mulatory activity of the partially purified thymus extracts. Certain other thymic factors have also been analyzed. Thymosin [34, including distribution and biosynthesis in many different vertebrate cells and tissues, was presented by Dr. B. L. Horecker (New Jersey). The significance of spermidine and spermine as regulators of thymus extract function was discussed by Dr. K. Folkers (Texas). The concept of small thymic peptides as immunoregulatory agents was reviewed by Dr. C. Birr (West Germany). Several short papers were included on the possible role of the thymus in AIDS. The second session, co-chaired by Drs. R. Gallo and M. Chirigos (Maryland), focused on the chemistry and biology of lymphokines. Dr. S. Mizel (Pennsylvania) described the preparation of antibodies against interleukin 1. Dr. T. D. Copeland (Maryland) characterized thymus cell growth factor obtained from continuous cell cultures of thymus cells in vitro using immunoaffinity methods. Dr. S. Rosenberg (Maryland) reviewed the role of lymphokines and adoptive immunotherapy concerning both experimental animals and man. The biological properties of interleukin 3, a soluble factor from T cells that activates other T cells, was illustrated by Dr. J. Ihle (Maryland). Colony stimulating factor, which activates mononuclear phagocytes, was described by Dr. E. R. Stanley (New York). Lymphotoxins, their nature, and their role in immunity was presented by Dr. G. Granger (California). Purification of human lymphotoxins from a tumor cell line was discussed by Dr. B. Aggarwal (California). The third session, co-chaired by
Drs. J. Oppenheim (Maryland) and A. deWeck (Switzerland), highlighted the immunoregulation and the role of various factors, such as thymosin extracts and lymphokines. Dr. deWeck discussed aging as related to lymphocyte receptors, lymphokines, and lymphocytes. Dr. W. Ershler (Vermont) reviewed the role of thymosin in augmenting antibody formation by lymphocytes from elderly individuals. Dr. K. A. Smith (New Hampshire) dealt with interleukins as immunoregulatory factors. Drs. N. Hall (Washington, D.C.) and R. Rebar (California) reviewed the interactions between the immune system and the central nervous system through immunomodulatory factors. Dr. E. Pick (Israel) discussed various biochemical activities of lymphokines. Dr. C. Sorg (West Germany) elaborated on macrophage migration inhibitory factor. Dr. J. Vilcek (New York) described human immune interferon internalization and specific cell receptors. The fourth session, co-chaired by Drs. E. Garaci (Italy) and J. Hadden (Florida), concentrated on the pharmacology of various interieukins. Dr. B. W. Papermaster (Missouri) reviewed purification and biological properties of human lymphoblastoid macrophage activating factors, while Dr. G. J. Todaro (Washington) discussed tumor inhibitory factors produced by tumor cells. Dr. Djerassi (Pennsylvania) reviewed the properties of inhibitory factors released by normal cells in culture. The effects of thymosin on cell-mediated immunity, immunoregulatory T cells, and tumor cells were explored by a number of speakers.
MEETING REPORT Thymic Hormones and Lymphokines '83, May 31-June 3, 1983, Washington, D.C. Herman Friedman, Ph.D. Department of Medical Microbiology and Immunology University of South Florida Tampa. Florida
The meeting consisted of five halfday plenary sessions, five poster sessions, and a final panel discussion summarizing the various topics. The first plenary session, co-chaired by Drs. J. F. Bach (France) and H. Friedman (Florida), dealt with the chemistry of thymic hormones. Recent developments in the biochemistry of thymulin, a nonapeptide, initially identified by Bach and his group, was reviewed by M. Dardanne (France). Thymulin, the new term for the biological active serum peptide formally called Factor Thymique Serique, readily binds to the metal zinc. The conjugate of the nonapeptide and zinc accounts for all of the biologic activity of the native peptide. It has been synthesized and shown to activate immature lymphoid cells. The biochemistry and structure of thymosin factors were described by Dr. T. Low (Washington, D.C.). A large family of peptides has now been identified in the original thymosin fraction-5, which has been used both in experimental animal and human studies in terms of modulation of thymus function. Thymosin txI has been sequenced and synthesized and shown to have much of the immunosti-
128
0197-1859/83/S03.00
Clinical ImmunologyNewsletter
The final plenary session, co-chaired by Drs. R. Oldham (Maryland) and P. Chretien (Maryland), dealt with clinical applications of thymosin and interleukins. A large number of studies have now been performed in various medical centers concerning factors such as interferon, interleukins, lym-
Editors: Herman Friedman Mario R. Escobar Noel R. Rose
phokines, and thymus extracts, including thymulin, thymosin fraction-5, and thymosin al- At the present time, there is no general consensus as to whether or not significant augmentation of immune responses occurs with these materials and whether or not there are significant clinical improve-
ments in patients with various diseases, including cancer and immunodeficiencies. It was generally agreed that further studies are warranted to ascertain the usefulness of these factors in clincial situations.
Contributing Editors: John R. Kateley, Jr., Ph.D., Edward W. Sparrow Hospital; Stanley S. Lefkowitz, Ph.D., Texas Tech University; Bruce S. Rabin, M.D., Ph.D., University of Pittsburgh Medical School; Gilberto E. Rodriguez, M.D., Medical College of Virginia; lohn L. Sever, M.D., Ph.D., National Institutes of Health; Steven Specter, Ph.D., University of South Florida College of Medicine; Roy W. Stevens, Ph.D., State of New York Department of Health; Gabriel W. Virella, M.D., Ph.D., Medical University of South Carolina; Kenneth W. Walls, Ph.D., Centers for Disease Control; Theresa L. Whiteside, Ph.D., University of Pittsburgh Medical School. Consulting Editors: Joseph A. Bellanti, M.D., Georgetown University School of Medicine; Rebecca H. Buckley, M.D., Duke University Medical Center; John L. Fahey, M.D., UCLA School of Medicine; H. Hugh Fudenberg, M.D., Medical University of South Carolina; Erwin Neter, M.D., Children's Hospital and SUNY; Gerald M. Penn, M.D., Ph.D., Grant Hospital; Robert F. Ritchie, M.D., Foundation for Blood Research; Andor Szentivanyi, M.D., University of South Florida College of Medicine; Norman Talal, M.D., University of Texas Health Science Center; Eng M. Tan, M.D., Scripps Clinic and Research Foundation; Edmond J. Yunis, M.D., Sidney Farber Cancer Institute. Clinical hnmunology Newsletter is published monthly by Elsevier Science Publishing Co., Inc., 52 Vanderbilt Avenue, New York, NY 10017. Subscription rate is $50.00 for 12 issues including postage and handling in the United States and Canada. Add $14.00 for postage (airmail) in Mexico and Europe and $16.00 for the rest of the world. This newsletter has been registered with the Copyright Clearance Center, Inc. Consent is given for copying articles for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition that the copier pay through the Center the per-page fee stated in the code on each page for copying beyond that permitted by the U.S. Copyright Law. If no code appears on an article, the author has not given broad consent to copy. and permission to copy must be obtained directly from the author. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.
ISSN 0197-1859 CIMNDC 4(9) 113-129, 1983
Address orders, changes of address, and claims for missing issues to Journals Fulfillment Department, Elsevier Science Publishing Co., Inc., 52 Vanderbilt Avenue, New York, NY 10017. Claims for missing issues can be honored only up to three months for domestic addresses and six months for foreign addresses. Duplicate copies will not be sent to replace ones undelivered due to failure to notify Elsevier of change of address.
Elsevier Biomedical
Postmaster: Send address changes to Clhffcal hnmunology Newsletter, Elsevier Science Publishing Co., Inc., 52 Vanderbilt Avenue, New York, NY 10017.
O 1983 Elsevier Science Publishing Co., Inc.
© 1983 by Elsevier Science PublishingCo.. Inc.
0197-]859'83/503.00
129